相关实验视频

Updated: May 5, 2026

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice

Published on: May 4, 2015

PTUPB改善了阿尔茨海默病的认知功能,与增强脑血管肌性反应和减弱血管重塑有关

Gilbert C Morgan¹, Andrew Gregory¹, Chengyun Tang¹

¹Department of Physiology, Medical College of Georgia, Augusta University, 1462 Laney Walker Blvd, Augusta, GA, 30912, USA.

|February 6, 2026

概括

一种新的双重抑制剂,PTUPB,向可溶性环氧化酶 (sEH) 和循环氧化原酶-2 (COX-2),改善了阿尔茨海默病 (AD) 的老鼠的认知功能和脑血管健康.

科学领域:

神经科学是一个神经科学.
药理学药理学是一个学科.
血管生物学血管生物学

背景情况:

遗传研究将EPHX2 (sEH) 和PTGS2 (COX-2) 与阿尔茨海默病 (AD) 联系起来.
在AD中sEH和COX-2水平升高与神经退行,质激活,血管功能障碍和炎症相关.

研究的目的:

评估一种新型双重sEH/COX-2抑制剂的治疗潜力,PTUPB.
评估PTUPB对AD大鼠模型中脑血管功能和认知表现的影响.

主要方法:

在TgF344-AD大鼠中,用PTUPB口服 (2 mg/kg/天) 治疗了25天.
用新型物体识别测试来评估认知功能.
脑血管功能使用中脑动脉 (MCA) 压力肌图进行评估.
进行了脑血管光滑肌细胞的转录分析.

主要成果:

在AD大鼠中,PTUPB治疗显著改善了识别记忆.
在AD大鼠中,PTUPB恢复了肌源性反应,并增加了MCA阻抗能力.
转录组分析显示,PTUPB调节了参与血管收缩,重塑,炎症和氧化应激的基因.

结论:

使用PTUPB对sEH和COX-2的双抑制可以提高AD患者的认知功能.
通过增强肌源性反应和减弱血管重塑,PTUPB可以改善脑血管功能.
PTUPB显示出作为治疗AD相关的大脑血管功能障碍的治疗剂的希望.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.循环氧基因酶-2 的作用.肌源性反应的反应可溶性环氧化酸酶是可溶的环氧化酸酶.血管改造是指进行血管改造.

更多相关视频

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

相关概念视频

Long-term Potentiation

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.

Long-term Potentiation

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...